If your MS has affected your walking, your healthcare team can determine if AMPYRA is right for you. You can also assess your walking using a simple set of questions, then share these results with your doctor. Do not take AMPYRA if you have ever had a seizure or have kidney problems.

People have been taking AMPYRA for over 5 years as part of continuous safety trials and AMPYRA has been evaluated for safety in over 900 people with MS.⁶

You may experience some side effects with AMPYRA^® (dalfampridine).

These can include serious side effects, such as seizures or kidney or bladder infections.

The most common side effects of AMPYRA are:

• urinary tract infection
• trouble sleeping (insomnia)
• dizziness
• headache
• nausea
• weakness
• back pain
• problems with balance
• multiple sclerosis relapse
• burning, tingling or itching of the skin
• irritation in the nose and throat
• constipation
• indigestion
• pain in the throat

Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of AMPYRA. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

If you live in the US and cannot afford AMPYRA, you may qualify for help through the Patient Assistance Program. This program may be able to reimburse you for part or all of your medication. To find out if you qualify, call 1-888-881-1918.

You can take AMPYRA alone or with other MS medications. Always check with your doctor before taking any new medication. Do not take AMPYRA together with other aminopyridine medications, including compounded 4-aminopyridine (sometimes called 4-AP, fampridine).

AMPYRA^® (dalfampridine) Extended Release Tablets has a Risk Evaluation and Mitigation Strategy, or REMS, program. What this means is that the Food and Drug Administration (FDA) and Acorda Therapeutics agreed that certain important information about AMPYRA^® needs to be communicated to healthcare providers and patients.

The goals of AMPYRA’s REMS program are:

• Inform healthcare providers about the risk of drug-associated seizures in patients treated with AMPYRA.
• Inform healthcare providers about the change of the name from fampridine to dalfampridine upon approval of the drug.
• Inform patients about the serious risks associated with use of AMPYRA.

AMPYRA’s REMS program consists of a Medication Guide for patients and communications plan for healthcare professionals.

A patient Medication Guide is a resource to inform patients of the risks associated with taking a drug, possible side effects of the drug and the best way to safely take their medication. Click here to view the Patient Medication Guide for AMPYRA.

The communications plan for AMPYRA consisted of Acorda Therapeutics sending letters to potential prescribers of AMPYRA and to pharmacists who would be dispensing AMPYRA to make sure that they were informed of the drug-associated risks as well as the change in the name. Click here to view the REMS information.

AMPYRA^® is a medication indicated as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed.

AMPYRA isn't an infusion or injection. It's a tablet, taken twice a day by mouth about 12 hours apart. AMPYRA has been tested in people with the major types of MS. Patients with a history of seizure or with kidney problems must not take AMPYRA.

How AMPYRA works is not completely understood.

In MS, the body's immune system mistakenly attacks the protective coating around nerve fibers, called myelin.² When myelin is lost or damaged, potassium channels on the nerves open, and potassium leaks out.^3,4 This can weaken or distort the messages being sent from the brain to the rest of the body, and in some people, this can lead to walking difficulties.⁵

In animal studies, AMPYRA has been shown to help stop potassium leakage from the nerve fibers. This strengthens the signals that the brain sends through nerves whose myelin has been lost or damaged.

AMPYRA can cause seizures. Your chance of having a seizure is higher if you take too much AMPYRA or if you have kidney problems.

Do not take AMPYRA if you have ever had a seizure. Before taking AMPYRA tell your doctor if you have kidney problems.

Take AMPYRA exactly as prescribed by your doctor.

Stop taking AMPYRA and call your doctor right away if you have a seizure while taking AMPYRA.

Take one tablet of AMPYRA 2 times each day about 12 hours apart. Do not take more than 2 tablets of AMPYRA in a 24-hour period.

You should know that financial assistance may be available. To find out if you qualify for the Reimbursement Assistance or the Patient Assistance Program, call 1-888-881-1918.

In addition, AMPYRA Patient Support Services can provide you with the information and support you need regarding your treatment. Call 1-888-881-1918.

To find out more about how the drug works, visit How AMPYRA Works.

For what to expect with AMPYRA, visit What to Expect.

AMPYRA is a tablet, taken twice a day about every 12 hours, with or without food. It's important to remember not to divide, crush, chew or dissolve AMPYRA tablets. Be sure to follow your doctor's instructions on how to take AMPYRA.

Yes. It was fampridine-SR in clinical trials and is FDA-approved and marketed as AMPYRA^® (dalfampridine) Extended Release Tablets. They have the same active ingredient.

You should never share your medicine with others or keep expired or unused drugs in your home. If you have any AMPYRA that has expired or that you will not be using, you may want to consider taking advantage of community drug take-back programs. These programs allow the public to bring unused drugs to a central location for proper disposal. Information about take-back program can generally be found in your city's or county's government's household trash and recycling service (see blue pages in phone book). When in doubt about proper disposal, talk to your pharmacist. You can also find more information on the FDA website about proper disposal of drugs at the following address: http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm101653.htm

No. Before you take AMPYRA, tell your doctor if you're taking, or have been taking compounded 4-aminopyridine. AMPYRA and compounded 4-aminopyridine have the same active ingredient. Do not take AMPYRA if you are taking other medications that include compounded 4-aminopyridine (fampridine, 4-AP).